Other research analysts also recently issued research reports about the stock. ValuEngine raised shares of ProQR Therapeutics from a hold rating to a buy rating in a report on Wednesday, October 2nd. Zacks Investment Research raised shares of ProQR Therapeutics from a hold rating to a strong-buy rating and set a $10.00 target price for the company in a report on Wednesday, August 14th. Chardan Capital reaffirmed a buy rating and issued a $25.00 target price on shares of ProQR Therapeutics in a report on Friday, October 11th. Royal Bank of Canada reaffirmed a buy rating and issued a $27.00 target price on shares of ProQR Therapeutics in a report on Sunday, August 11th. Finally, Citigroup dropped their target price on shares of ProQR Therapeutics from $40.00 to $33.00 and set a buy rating for the company in a report on Tuesday. One analyst has rated the stock with a sell rating, six have given a buy rating and one has given a strong buy rating to the stock. ProQR Therapeutics presently has an average rating of Buy and an average price target of $25.83.
ProQR Therapeutics stock traded up $0.22 during mid-day trading on Thursday, hitting $8.40. The stock had a trading volume of 487,500 shares, compared to its average volume of 221,525. The firm has a market capitalization of $328.79 million, a P/E ratio of -6.51 and a beta of 0.24. The company has a current ratio of 7.01, a quick ratio of 7.01 and a debt-to-equity ratio of 0.18. The firm’s 50 day moving average is $6.85 and its 200 day moving average is $8.61. ProQR Therapeutics has a one year low of $5.49 and a one year high of $20.00.
ProQR Therapeutics Company Profile
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome.
See Also: What is the Quick Ratio?
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.